## A tumor test to guide PARP inhibitor treatment decisions





Myriad Genetic Laboratories, Inc. 320 Wakara Way - Salt Lake City, Utah 84108 PH: +1 (877) 283-6709 - FX: +1 (801) 883-8998 www.myriad.com

Outside U.S.A

C	F	IVD

EC REP

Myriad International GmbH Nattermannallee 1

MyChoice® CDx	Plu
UDD Componion Diagnostic Tost	

HRD Companion Diagnostic Test

Affix one bar code label here

Test Request Form Email: CustomerSupp	port@myriadgenetics.e	eu 50	829 Cologne, Germany			
To avoid delays please complete entire form	) Please print all i	nformation i	n BLOCK LETTERS			
Patient			Ordering physician	***********		
Date of birth (DD-MMM-YYYY):			Last name:		Degree:	
Sex assigned at birth: ☐ Female ☐ Male Patient ID:			First name:		Clinical ID:	
Legal name (Last):			Institution:			
Legal name (First):			Street, no:			
Billing information			City, postal code: Day phone:			
			Country:		Fax:	
Payor ID: or			E mails			
research #: or			E-mail:			
voucher #:						
Test requested  Intended Use - Myriad Genetics MyChoice® CDx Plus is a			and the other addresses and a sign of the side of			
on a panel of genes and/or detects genomic instability the results of a subset of these genes and/or the Geno become eligible for treatment with specific therapies in a in accordance with professional guidelines in oncology for more detailed information on the Myriad MyChoice® (  Test option  Analysis of GIS + BRCA1/2	using DNA extracted in the control of the control o	ed from tumo re (GIS) Statu e approved th ignant solid t erefer to the ing (Internal)	or specimens. Homologous Records. The test may be used as a cordinary product labeling. Resulting and the second s	mbination Defici mpanion diagno	ency (HRD) is determined by assessing ostic to identify patients who are or may	
☐ Analysis of GIS + BRCA1/2 + 13 additional genes	MyChoice Europe					
Authorized signature (Physician / healthcare	provider)					
	oned above. I hereb an / healthcare prov	by attest that t	the person listed in the ordering p			
Clinical information Please provide the follow	ing information:					
<ul> <li>□ Ovarian cancer (Ovary, fallopian tube, peritoneum)</li> <li>□ Breast cancer</li> <li>□ Bone marrow transplant recipient (check if applicable</li> </ul>	_		_ Date of biopsy/surgery (DD-M □ Allogeneic	MM-YYYY):		
Forward this Test	Request Form t	o the labor	ratory where the tumor spe	ecimen is loca	ated.	
Specimen information: to be complete Samples should ideally contain at least 30% tumor cells in t Insufficient tumor DNA content in the provided tumor samp component of the test.	tissue or fluid sampl	es by patholo	gic review. For a specime		hipping Instructions sheet) please contact testkit@myriadgenetics.e	
Tissue type submitted (e.g. Ovary):		ID*				
Specimen provided is <b>fixed tissue</b> *  *Only fixed tissues can be tested using Myriad MyChoice® CDx Plus.  Formalin Fixed Paraffin Embedded (FFPE) section(s) are preferred when available, however other fixatives can also be tested.			* Specimen identification number as it appears on the tissue blocks or slides submitted to Myriad.  Identifiers provided must match exactly to the sample submitted and the pathology report or testing will be delayed.			
Please	note: a copy of the	pathology re	eport must be submitted with sp	ecimen		
Tissue return						
I request the remaining tissue to be returned.*  Name:	Address:					
E-mail / phone:			* If an address is not provided, ar	ny tissue remaining at	fter testing will be discarded and not be returnable.	
Internal use only: Bill Institution BIE						

Sex assigned at birth is a label given to an individual at birth, typically "male" or "female".

A legal name identifies a person for legal and administrative purposes. It is recorded on a birth certificate, marriage certificate, or other government issued document that records a name change.